1447740-82-0

Upstream product

• 171567-86-5 (R)-2-((methoxycarbonyl)amino)-3-methylbutanoic acid 
• 1447940-13-7 (1S,1'S)-1,1'-(5,5'-(biphenyl-4,4'-diyl)bis(oxazole-5,2-diyl))bis(2-methylpropane-1,1-diyl)dicarbamate 
• 1447940-12-6 benzyl (1S,1'S)-1,1'-(5,5'-(biphenyl-4,4'-diyl)bis(oxazole-5,2-diyl))bis(2-methylpropane-1,1-diyl)dicarbamate 
• 1149-26-4 (S)-N-(benzyloxycarbonyl)valine 
• 5467-72-1 α-amino-4-bromoacetophenone hydrochloride 

Relevant academic research and scientific papers

Hepatitis C Virus Inhibitors

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

Hepatitis C Virus Inhibitors

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.